Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,093 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.
Schwartz GG, Szarek M, Bittner VA, Diaz R, Goodman SG, Jukema JW, Landmesser U, López-Jaramillo P, Manvelian G, Pordy R, Scemama M, Sinnaeve PR, White HD, Gabriel Steg P; ODYSSEY Outcomes Committees and Investigators. Schwartz GG, et al. Among authors: jukema jw. J Am Coll Cardiol. 2021 Aug 3;78(5):421-433. doi: 10.1016/j.jacc.2021.04.102. J Am Coll Cardiol. 2021. PMID: 34325831 Free PMC article. Clinical Trial.
The Asp9 Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis. REGRESS Study Group, Interuniversity Cardiology Institute, Utrecht, The Netherlands. Regression Growth Evaluation Statin Study.
Jukema JW, van Boven AJ, Groenemeijer B, Zwinderman AH, Reiber JH, Bruschke AV, Henneman JA, Molhoek GP, Bruin T, Jansen H, Gagné E, Hayden MR, Kastelein JJ. Jukema JW, et al. Circulation. 1996 Oct 15;94(8):1913-8. doi: 10.1161/01.cir.94.8.1913. Circulation. 1996. PMID: 8873668 Clinical Trial.
Modulation of lipoprotein(a) atherogenicity by high density lipoprotein cholesterol levels in middle-aged men with symptomatic coronary artery disease and normal to moderately elevated serum cholesterol. Regression Growth Evaluation Statin Study (REGRESS) Study Group.
Cobbaert C, Jukema JW, Zwinderman AH, Withagen AJ, Lindemans J, Bruschke AV. Cobbaert C, et al. Among authors: jukema jw. J Am Coll Cardiol. 1997 Nov 15;30(6):1491-9. doi: 10.1016/s0735-1097(97)00353-7. J Am Coll Cardiol. 1997. PMID: 9362407 Free article. Clinical Trial.
B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth Evaluation Statin Study (REGRESS).
de Groot E, Jukema JW, Montauban van Swijndregt AD, Zwinderman AH, Ackerstaff RG, van der Steen AF, Bom N, Lie KI, Bruschke AV. de Groot E, et al. Among authors: jukema jw. J Am Coll Cardiol. 1998 Jun;31(7):1561-7. doi: 10.1016/s0735-1097(98)00170-3. J Am Coll Cardiol. 1998. PMID: 9626835 Free article. Clinical Trial.
Secondary prevention with folic acid: effects on clinical outcomes.
Liem A, Reynierse-Buitenwerf GH, Zwinderman AH, Jukema JW, van Veldhuisen DJ. Liem A, et al. Among authors: jukema jw. J Am Coll Cardiol. 2003 Jun 18;41(12):2105-13. doi: 10.1016/s0735-1097(03)00485-6. J Am Coll Cardiol. 2003. PMID: 12821232 Free article. Clinical Trial.
Genetic predictive factors in restenosis.
Monraats PS, R P Agema W, Jukema JW. Monraats PS, et al. Among authors: jukema jw. Pathol Biol (Paris). 2004 May;52(4):186-95. doi: 10.1016/j.patbio.2004.02.003. Pathol Biol (Paris). 2004. PMID: 15145131 Review.
Serum levels of type II secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study.
Boekholdt SM, Keller TT, Wareham NJ, Luben R, Bingham SA, Day NE, Sandhu MS, Jukema JW, Kastelein JJ, Hack CE, Khaw KT. Boekholdt SM, et al. Among authors: jukema jw. Arterioscler Thromb Vasc Biol. 2005 Apr;25(4):839-46. doi: 10.1161/01.ATV.0000157933.19424.b7. Epub 2005 Feb 3. Arterioscler Thromb Vasc Biol. 2005. PMID: 15692105
1,093 results